Replies to post #137658 on Biotech Values

[kamehameha]

looks promising, good chances for an all-oral treatment, GILD needs to look out for alternatives to VRUS compounds.

[DewDiligence]

Quiz: In what way does VRTX’s newly announced phase-2b study differ from nearly every HCV study VRTX has conducted during the past few years?